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The overwhelming majority of human cancer deaths are 
attributable to distant metastases, rather than the primary 
tumors  from  which  these  malignant  lesions  originate. 
Metastases  arise  through  the  completion  of  a  series  of 
complex, interrelated cell biological events - collect  ively 
termed  the  ‘invasion-metastasis  cascade’  -  involving  the 
dissemination of tumor cells to anatomically distant loci 
and the subsequent adaptation of these tumor cells to the 
foreign microenvironments encountered there [1]. Molecular 
mediators  of  these  events  have  recently  begun  to  be 
identified; however, our under  standing of the pathogenesis 
of metastatic disease remains woefully incomplete.
One class of molecules that have been documented to 
have a crucial role in regulating the invasion-metastasis 
cascade  are  microRNAs  (miRNAs).  miRNAs  are  an 
evolutionarily conserved family of small regulatory RNAs 
that  pleiotropically  suppress  gene  expression  through 
sequence-specific  interactions  with  the  3’  untranslated 
regions (UTRs) of cognate mRNA targets [2]. Research 
conducted  over  the  past  3  years  has  succeeded  in 
elucidating various individual miRNAs that serve either 
to enhance or to impair discrete steps of the metastatic 
process [3].
Two  recent  studies  [4,5]  have  now  evaluated  the 
consequences for metastasis of a global reduction in the 
levels of all the miRNAs produced by a cancer cell. More 
specifically,  these  investigators  have  discovered  signal 
transduction pathways that lead to downregulation of the 
miRNA biogenesis enzyme Dicer and have then assessed 
the repercussions of impaired Dicer function for breast 
carcinoma metastasis (Figure 1). Dicer is an RNase III 
family endonuclease that is required for the post-trans-
criptional  processing  of  miRNAs  to  their  mature, 
functionally active form [2]. Previous studies have shown 
that  global  miRNA  levels  are  often  reduced  in  human 
tumor speci  mens [6]; moreover, experimental inhibition 
of Dicer or other components of the miRNA biogenesis 
machinery  has  been  reported  to  accelerate  primary 
tumor develop  ment [7]. However, the recent studies from 
the labora  tories of Piccolo [4] and Flores [5] are the first 
to address the functional contributions of Dicer speci-
fically to metastatic progression.
Biting the hand that feeds: miRNA-mediated 
suppression of Dicer expression promotes metastasis
Piccolo and coworkers [4] report that the miR-103/107 
family of miRNAs directly targets the mRNA encoding 
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Figure 1. A diagram of the known components of metastasis-
controlling signal transduction cascades that involve Dicer. 
While the suppressive effects of miR-31, miR-126, miR-206, and 
miR-335 on metastasis have been directly documented in vivo [8,9], 
the roles of miR-130 and miR-200 in metastasis are implied by in vitro 
studies [3,7], but have yet to be analyzed directly in vivo.
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enzyme  that  is  responsible  for  their  own  biosynthesis. 
miR-103/107 and Dicer levels were found to be inversely 
correlated  in  several  cancer  cell  lines  and  in  tissue 
specimens  derived  directly  from  human  breast  cancer 
patients. Surprisingly, although miR-103/107 expression 
was  positively  associated  with  the  propensity  to  suffer 
from  metastatic  relapse  in  human  breast  tumors,  no 
significant correlation between Dicer levels and the risk 
of developing metastatic disease was found. This finding 
implies  that  miR-103/107  can  pleiotropically  regulate 
other,  still-unidentified  mRNA  molecules  that  encode 
functions relevant to metastasis. Moreover, the authors 
[4] did not investigate the possibility of dynamic changes 
in Dicer and miR-103/107 levels arising from the feed-
back loop between them.
The authors [4] also discovered that overexpression of 
miR-103/107 enhanced the motility of breast carcinoma 
cells  in  vitro.  These  effects  on  cell  motility  could  be 
potently reversed via forced expression of Dicer, implying 
that the ability of miR-103/107 to enhance cell motility 
was  closely  tied  to  its  capacity  to  reduce  Dicer  levels. 
Further corroborating this finding was their observation 
that short hairpin RNA (shRNA)-mediated suppression 
of endogenous Dicer levels increased in vitro motility in 
these same breast carcinoma cells. Additionally, inhibi-
tion of miR-103/107 or overexpression of Dicer sufficed 
to  impair  the  in  vitro  motility  of  otherwise-aggressive 
breast cancer cell lines. It is intriguing that Dicer over-
expression  sufficed  to  enhance  cell  motility,  as  this 
suggests that Dicer catalytic activity can be rate-limiting 
for miRNA biogenesis - at least in the context of certain 
tumor cell lines.
miR-103/107  and  Dicer  also  influenced  the  in  vivo 
behaviors  of  breast  carcinoma  cells  grown  as  tumor 
xenografts.  More  specifically,  miR-107  overexpression 
endowed otherwise weakly metastatic breast cancer cells 
with heightened metastatic powers; these influences of 
miR-107 on metastasis were essentially abrogated by the 
concurrent forced expression of Dicer. shRNA-conferred 
suppression of the Dicer-encoding mRNA also increased 
metastasis  formation  in  these  xenograft  studies  [4].  In 
addition,  the  authors  observed  that  either  inhibition  of 
miR-103/107  or  overexpression  of  Dicer  reduced  the 
metastatic  potential  of  otherwise-metastatic  mammary 
carcinoma cell lines in vivo. These results show that Dicer 
expression  is  both  necessary  and  sufficient  to  impair  a 
variety of malignant attributes in vitro and in vivo, and that 
modulation of Dicer levels can explain a significant pro-
por  tion of the effects of miR-103/107 on these same traits.
Finally, Piccolo and colleagues [4] showed that miR-107 
overexpression or shRNA-mediated suppression of Dicer 
triggered an epithelial-mesenchymal transition (EMT) in 
normal mammary epithelial cells. Because the EMT has 
previously  been  linked  to  the  promotion  of  motile 
behavior in carcinoma cells [1], they reasoned that loss of 
Dicer expression might enhance cell motility through the 
induction of an EMT, presumably by disrupting miRNA-
controlled fate decisions. Indeed, they found that modu-
lating miR-103/107 levels altered the activity of miR-200 - 
a crucial EMT-inhibitory miRNA [3] - in their cell culture 
models.  However,  the  authors  [4]  did  not  address  the 
relevance of these miR-200-dependent signaling events 
for in vivo metastatic abilities, nor did they determine the 
contributions of other known anti-metastatic miRNAs - 
such as miR-31, miR-126, miR-206 and miR-335 [8,9] - 
for  mediating  the  observed  anti-malignant  responses. 
Together, the work of Piccolo and colleagues [4] shows 
that  Dicer  can  be  post-transcriptionally  suppressed  by 
miR-103/107,  leading  to  enhanced  metastatic  capacity 
following  the  dampening  activity  of  the  metastasis-
suppressing Dicer enzyme.
Upregulation of Dicer expression by TaP63 
suppresses metastasis
Dicer expression levels are controlled by several different 
signaling  pathways.  The  recent  findings  of  Flores  and 
coworkers [5] - which highlight one mechanism by which 
transcription of the Dicer gene is controlled - are there-
fore highly significant. In this study, the authors [5] noted 
that mice engineered to be genetically deficient for the 
p53-related  transcription  factor  TaP63  developed 
metastatic tumors with an increased frequency. In fact, 
whereas TaP63+/- and TaP63-/- mice contracted metastatic 
carcinomas with an equivalent prevalence, the TaP63+/- 
animals  were  at  an  even  higher  risk  for  developing 
metastatic  sarcomas  than  were  the  TaP63-/- mice;  the 
mecha  nistic rationale underlying this observation remains 
imprecisely defined and merits further investigation [5].
The  Flores  laboratory  [5]  hypothesized  -  because  of 
similarities of the haploinsufficiency of TaP63 for tumor 
suppression,  and  also  of  the  embryonic  lethality  of 
TaP63-/- mice on an enriched C57Bl/6 background before 
embryonic  day  8.5,  with  the  previously  reported 
corresponding phenotypes of Dicer conditional knockout 
animals [10] - that TaP63 and Dicer might operate within 
the same biochemical pathway. Indeed, they discovered 
that levels of the Dicer-encoding mRNA were dramati-
cally reduced in cell lines derived from TaP63-deficient 
animals;  furthermore,  low  expression  of  TaP63  was 
correlated with low Dicer levels in patient-derived meta-
static human tumor specimens. In addition, the authors 
[5] showed using chromatin immuno  precipi  tation (ChIP) 
analyses  that  TaP63  can  bind  directly  to  the  promoter 
region of Dicer. Therefore, TaP63 can directly regulate 
expression levels of Dicer.
In  functional  assays,  the  authors  [5]  discovered  that 
forced  expression  of  Dicer  reversed  the  increased 
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Increased  invasion  was  also  triggered  by  the  shRNA-
conferred suppression of endogenous Dicer levels in the 
same in vitro assays. However, the effects of modulating 
Dicer levels on the in vivo metastatic behaviors of carci-
noma cells were not investigated in this study [5]; this is a 
crucial topic for future investigation, as rigorous analysis 
of metastatic attributes requires detailed in vivo analyses.
The authors [5] also undertook to identify additional 
transcriptional  targets  of  TaP63  that  might  also  be 
important for mediating its influences on the aggressive 
behaviors  of  carcinoma  cells.  One  such  downstream 
effector of TaP63 was found to be the miRNA miR-130b. 
Direct  binding  of  TaP63  to  the  putative  miR-130b 
promoter  sequence  was  documented  by  ChIP  experi-
ments. Also, in functional assays, inhibition of miR-130b 
resulted  in  increased  motility  in  vitro  -  a  phenotype 
reminiscent  of  the  cell-biological  changes  elicited  by 
modulation of the expression levels of either TaP63 or 
Dicer  itself.  The  augmented  in  vitro  invasiveness 
observed in cell lines derived from TaP63-deficient mice 
could be completely reversed by the concomitant over-
expression of miR-130b and Dicer. The data of Flores and 
colleagues [5] therefore imply that TaP63 can alter certain 
cellular  behaviors  -  such  as  invasiveness  -  that  are 
believed  to  be  important  for  the  acquisition  of  a 
metastatic phenotype via the coordinate transcriptional 
regulation of Dicer and miR-130b.
Conceptual and therapeutic implications
The work of the Piccolo [4] and Flores [5] laboratories 
reveal  that  Dicer  functions  as  a  potent  suppressor  of 
metastatic attributes in breast carcinoma cells. Given the 
diverse  roles  of  various  individual  miRNAs  during  the 
invasion-metastasis cascade - including both metastasis-
promoting effects and metastasis-suppressive influences 
[3]  -  it  is  striking  that  a  global  reduction  of  miRNA 
activity results in such a clear and unambiguous pheno-
type in multiple different breast carcinoma cell lines. An 
important  direction  for  future  research  will  involve 
determining  whether  Dicer  has  a  similar  metastasis-
suppressive role in carcinomas derived from tissue types 
other  than  the  breast.  From  a  practical  standpoint, 
however, it seems highly likely that the critical functions 
orchestrated by miRNAs in a wide spectrum of different 
tissue  and  cell  types  will  preclude  the  development  of 
anti-Dicer-based  therapeutic  agents  designed  to  block 
metastatic disease.
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